vs
Side-by-side financial comparison of NovoCure Ltd (NVCR) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $174.1M, roughly 1.2× NovoCure Ltd). ROGERS CORP runs the higher net margin — 2.2% vs -40.9%, a 43.1% gap on every dollar of revenue. On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs 5.2%). Over the past eight quarters, NovoCure Ltd's revenue compounded faster (7.6% CAGR vs -3.3%).
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
NVCR vs ROG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $174.1M | $200.5M |
| Net Profit | $-71.1M | $4.5M |
| Gross Margin | 77.6% | 32.2% |
| Operating Margin | — | — |
| Net Margin | -40.9% | 2.2% |
| Revenue YoY | 12.3% | 5.2% |
| Net Profit YoY | -107.3% | 421.4% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $174.1M | $200.5M | ||
| Q4 25 | $174.3M | $201.5M | ||
| Q3 25 | $167.2M | $216.0M | ||
| Q2 25 | $158.8M | $202.8M | ||
| Q1 25 | $155.0M | $190.5M | ||
| Q4 24 | $161.3M | $192.2M | ||
| Q3 24 | $155.1M | $210.3M | ||
| Q2 24 | $150.4M | $214.2M |
| Q1 26 | $-71.1M | $4.5M | ||
| Q4 25 | $-24.5M | $4.6M | ||
| Q3 25 | $-37.3M | $8.6M | ||
| Q2 25 | $-40.1M | $-73.6M | ||
| Q1 25 | $-34.3M | $-1.4M | ||
| Q4 24 | $-65.9M | $-500.0K | ||
| Q3 24 | $-30.6M | $10.7M | ||
| Q2 24 | $-33.4M | $8.1M |
| Q1 26 | 77.6% | 32.2% | ||
| Q4 25 | 75.8% | 31.5% | ||
| Q3 25 | 73.2% | 33.5% | ||
| Q2 25 | 73.9% | 31.6% | ||
| Q1 25 | 75.1% | 29.9% | ||
| Q4 24 | 79.2% | 32.1% | ||
| Q3 24 | 77.2% | 35.2% | ||
| Q2 24 | 77.0% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -23.2% | 3.5% | ||
| Q3 25 | -21.5% | 7.3% | ||
| Q2 25 | -24.9% | -33.3% | ||
| Q1 25 | -24.4% | -0.2% | ||
| Q4 24 | -39.3% | -6.6% | ||
| Q3 24 | -20.7% | 6.9% | ||
| Q2 24 | -22.3% | 5.3% |
| Q1 26 | -40.9% | 2.2% | ||
| Q4 25 | -14.1% | 2.3% | ||
| Q3 25 | -22.3% | 4.0% | ||
| Q2 25 | -25.3% | -36.3% | ||
| Q1 25 | -22.1% | -0.7% | ||
| Q4 24 | -40.9% | -0.3% | ||
| Q3 24 | -19.7% | 5.1% | ||
| Q2 24 | -22.2% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.22 | $0.20 | ||
| Q3 25 | $-0.33 | $0.48 | ||
| Q2 25 | $-0.36 | $-4.00 | ||
| Q1 25 | $-0.31 | $-0.08 | ||
| Q4 24 | $-0.61 | $-0.04 | ||
| Q3 24 | $-0.28 | $0.58 | ||
| Q2 24 | $-0.31 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $432.0M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $330.7M | $1.2B |
| Total Assets | $787.9M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $432.0M | $195.8M | ||
| Q4 25 | $93.5M | $197.0M | ||
| Q3 25 | $342.1M | $167.8M | ||
| Q2 25 | $149.6M | $157.2M | ||
| Q1 25 | $127.3M | $175.6M | ||
| Q4 24 | $163.8M | $159.8M | ||
| Q3 24 | $185.4M | $146.4M | ||
| Q2 24 | $164.8M | $119.9M |
| Q1 26 | $330.7M | $1.2B | ||
| Q4 25 | $340.5M | $1.2B | ||
| Q3 25 | $341.3M | $1.2B | ||
| Q2 25 | $349.4M | $1.2B | ||
| Q1 25 | $362.0M | $1.3B | ||
| Q4 24 | $360.2M | $1.3B | ||
| Q3 24 | $360.8M | $1.3B | ||
| Q2 24 | $361.8M | $1.3B |
| Q1 26 | $787.9M | $1.4B | ||
| Q4 25 | $804.3M | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.8M |
| Free Cash FlowOCF − Capex | — | $1.1M |
| FCF MarginFCF / Revenue | — | 0.5% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-18.0M | $46.9M | ||
| Q3 25 | $20.6M | $28.9M | ||
| Q2 25 | $-15.9M | $13.7M | ||
| Q1 25 | $-35.7M | $11.7M | ||
| Q4 24 | $-3.5M | $33.7M | ||
| Q3 24 | $10.4M | $42.4M | ||
| Q2 24 | $-1.7M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-22.9M | $42.2M | ||
| Q3 25 | $14.9M | $21.2M | ||
| Q2 25 | $-21.4M | $5.6M | ||
| Q1 25 | $-46.3M | $2.1M | ||
| Q4 24 | $-12.4M | $18.3M | ||
| Q3 24 | $-307.0K | $25.2M | ||
| Q2 24 | $-13.2M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -13.1% | 20.9% | ||
| Q3 25 | 8.9% | 9.8% | ||
| Q2 25 | -13.5% | 2.8% | ||
| Q1 25 | -29.9% | 1.1% | ||
| Q4 24 | -7.7% | 9.5% | ||
| Q3 24 | -0.2% | 12.0% | ||
| Q2 24 | -8.8% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 2.8% | 2.3% | ||
| Q3 25 | 3.4% | 3.6% | ||
| Q2 25 | 3.5% | 4.0% | ||
| Q1 25 | 6.8% | 5.0% | ||
| Q4 24 | 5.5% | 8.0% | ||
| Q3 24 | 6.9% | 8.2% | ||
| Q2 24 | 7.6% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
